Police say suspect in UnitedHealthcare CEO killing wasn't a client of the insurerEversource Energy stock underperforms Thursday when compared to competitorsATLANTA (AP) — President Joe Biden's administration announced Tuesday that the U.S. Department of Energy will make a $6.6 billion loan to Rivian Automotive to build a factory in Georgia that had stalled as the startup electric vehicle maker struggled to become profitable. It's unclear whether the administration can complete the loan before Donald Trump becomes president again in less than two months, or whether the Trump administration might try to claw the money back. Trump previously vowed to end federal electric vehicle tax credits , which are worth up to $7,500 for new zero-emission vehicles and $4,000 for used ones. Rivian made a splash when it went public and began producing large electric R1 SUVs, pickup trucks and delivery vans at a former Mitsubishi factory in Normal, Illinois, in 2021. Months later, the California-based company announced it would build a second, larger, $5 billion plant about 40 miles (64 kilometers) east of Atlanta, near the town of Social Circle. The R1 vehicles cost $70,000 or more. The company plans to produce R2 vehicles, a smaller SUV, in Georgia with lower price tags aimed at a mass market. The first phase of Rivian’s Georgia factory is projected to make 200,000 vehicles a year, with a second phase capable of another 200,000 a year. Eventually, the plant is projected to employ 7,500 workers. But Rivian was unable to meet production and sales targets and rapidly burned through cash. In March, the company said it would pause construction of the Georgia plant. The company said it would begin assembling its R2 SUV in Illinois instead. CEO RJ Scaringe said the move would allow Rivian to start selling the R2 sooner and save $2.25 billion in capital spending. Since then, German automaker Volkswagen AG said in June it would invest $5 billion in Rivian in a joint venture in which Rivian would share software and electrical technology with Volkswagen. The money eased Rivian's cash crunch. Tuesday's announcement throws a lifeline to Rivian's grander plans. The company said its plans to make the R2 and the smaller R3 in Georgia are back on and that production will begin in 2028. “This loan would enable Rivian to more aggressively scale our U.S. manufacturing footprint for our competitively priced R2 and R3 vehicles that emphasize both capability and affordability,” Scaringe said in a statement. The Energy Department said the loan would substantially boost electric vehicles made in the United States and support Biden’s goal of having zero-emission vehicles make up half of all new U.S. sales by 2030. “As one of a few American EV startups with light duty vehicles already on the road, Rivian’s Georgia facility will allow the company to reach production volumes that make its products more cost competitive and accelerate access to international markets,” the department said in a statement. The loan includes $6 billion, plus $600 million in interest that will be rolled into the principal. The money would come from the Advanced Technology Vehicles Manufacturing Loan Program, which provides low-interest loans to make fuel-efficient vehicles and components. The program has focused mostly on loans to new battery factories for electric vehicles under Biden, but earlier helped finance initial production of the Tesla Model S and Nissan Leaf, two pioneering electric vehicles. The loan program, created in 2007, requires a "reasonable prospect of repayment" of the loan. Under Biden, the program has announced deals totaling $33.3 billion, including $9.2 billion for massive battery plants in Tennessee and Kentucky for Ford’s electric vehicles. Democratic U.S. Sen. Jon Ossoff , who has been a vocal supporter of electric vehicle and solar manufacturing in Georgia, hailed Tuesday's announcement as “yet another historic federal investment in Georgia electric vehicle manufacturing.” Ossoff had asked Energy Secretary Jennifer Granholm to support the loan in July. “Our federal manufacturing incentives are driving economic development across the state of Georgia,” Ossoff said in a statement. Georgia Gov. Brian Kemp says his goal is to make Georgia a center of the electric vehicle industry. But the Republican has had a strained relationship with the Biden administration over its industrial policy, even as some studies have found Georgia has netted more electric vehicle investment than any other state. Kemp has long claimed that manufacturers were picking Georgia before Biden's signature climate law, the Inflation Reduction Act, was passed. Efforts to bring Rivian to Georgia predated the Biden administration and "our shared vision to bring opportunity to Georgia will remain no matter who resides in the White House or what party controls Congress,” Kemp spokesperson Garrison Douglas said Tuesday. The loan to Rivian could rescue one of the Kemp administration's signature economic development projects even as Biden leaves office. That could put Rivian and Kemp in the position of defending the loan if Trump tries to quash it. State and local governments offered Rivian an incentive package worth an estimated $1.5 billion in 2022. Neighbors opposed to development of the Georgia site mounted legal challenges. State and local governments spent around $125 million to buy and prepare the nearly 2,000-acre (810-hectare) site. The state also has completed most of $50 million in roadwork that it pledged. The pause at Rivian contrasts with rapid construction at Hyundai Motor Group’s $7.6 billion electric vehicle and battery complex near Savannah. The Korean automaker said in October that it had begun production in Ellabell, where it plans to eventually employ 8,500. Associated Press writer Matthew Daly in Washington contributed to this story.3d genie 。

None

INDIANAPOLIS (AP) — There's more than just school pride and bragging rights to all that bellyaching over who might be in and who might be out of college football 's first 12-team playoff. Try the more than $115 million that will be spread across the conferences at the end of the season, all depending on who gets in and which teams go the farthest. According to the College Football Playoff website , the 12 teams simply making the bracket earn their conferences $4 million each. Another $4 million goes to conferences whose teams get into the quarterfinals. Then, there's $6 million more for teams that make the semifinals and another $6 million for those who play for the title. Most of this bonanza comes courtesy of ESPN, which is forking over $1.3 billion a year to televise the new postseason. A lot of that money is already earmarked — more goes to the Big Ten and Southeastern Conference than the Big 12 or Atlantic Coast — but a lot is up for grabs in the 11 games that will play out between the opening round on Dec. 20 and the final on Jan. 20. In all, the teams that make the title game will bring $20 million to their conferences, all of which distribute that money, along with billions in TV revenue and other sources, in different ways. In fiscal 2022-23, the Big Ten, for instance, reported revenue of nearly $880 million and distributed about $60.5 million to most of its members. The massive stakes might help explain the unabashed lobbying coming from some corners of the football world, as the tension grows in advance of Sunday's final rankings, which will set the bracket. Earlier this week, Big 12 commissioner Brett Yormark lit into the selection committee, which doesn't have a single team higher than 15 in the rankings. That does two things: It positions the Big 12 as a one-bid league, and also threatens to makes its champion — either Arizona State or Iowa State — the fifth-best among conference titlists that get automatic bids. Only the top four of those get byes, which could cost the Big 12 a spot in the quarterfinals — or $4 million. “The committee continues to show time and time again that they are paying attention to logos versus resumes,” Yormark said this week, while slamming the idea of teams with two losses in his conference being ranked worse than teams with three in the SEC. The ACC is also staring at a one-bid season with only No. 8 SMU inside the cut line of this week's projected bracket. Miami's loss last week all but bumped the Hurricanes out of the playoffs, a snub that ACC commissioner Jim Phillips said left him “incredibly shocked and disappointed." “As we look ahead to the final rankings, we hope the committee will reconsider and put a deserving Miami in the field," Phillips said in a statement. The lobbying and bickering filters down to the campuses that feel the impact. And, of course, to social media. One of the most entertaining episodes came earlier this week when athletic directors at Iowa State and SMU went back and forth about whose team was more deserving. There are a few stray millions that the selection committee cannot really influence, including a $3 million payment to conferences that make the playoff. In a reminder that all these kids are going to school, after all, the conferences get $300,000 per football team that meets academic requirements to participate in the postseason. (That's basically everyone). Get poll alerts and updates on the AP Top 25 throughout the season. Sign up here . AP college football: https://apnews.com/hub/ap-top-25-college-football-poll and https://apnews.com/hub/college-footballNone

( MENAFN - EIN Presswire) Clinical Research Organization Global market Report 2024 - Market Size, Trends, And Global Forecast 2024-2033 The Business Research Company's Early Year-End Sale! Get up to 30% off detailed market research reports-for a limited time only! LONDON, GREATER LONDON, UNITED KINGDOM, December 13, 2024 /EINPresswire / -- The Business Research Company's Early Year-End Sale! Get up to 30% off detailed market research reports-limited time only! The Clinical Research Organization CRO market has been growing solidly in recent times. An industry forecast indicates an increase from $54.15 billion in 2023 to $59.41 billion in 2024 at a potent compound annual growth rate CAGR of 9.7%. This favorable progression during the historic period is chiefly attributed to factors like an aging global population, mounting prevalence of chronic conditions, globalization of clinical trials, a greater focus on orphan drug development, along with substantial government funding and grants. What Is the Future Outlook and Market Size for Clinical Research Organizations? The Clinical Research Organization market is forecasted to witness robust growth in the upcoming years. According to data projections, by 2028, the market will hit a staggering figure of $86.33 billion, with a compound annual growth rate CAGR at 9.8%. The primary factors driving growth throughout the forecasted period include shifting focus towards personalized medicine, an upsurge in clinical trials, expanding drug development pipelines, increased spending on pharmaceutical research and development, and the rising boom in biopharmaceuticals. Discover Key Insights and Market Trends with a Free Sample Report of the Global Clinical Research Organization Market: What Are the Key Market Drivers Catalyzing Growth in the CRO Market? A key driver instigating this growth trajectory is the burgeoning demand for personalized medicine. Personalized medicine, also known as precision medicine or individualized medicine, is an innovative approach to medical care that customizes treatments and interventions based on the unique characteristics of each patient. Due advancements in genomics and biotechnology, treatments have become more targeted and effective, catering specifically to individual genetic profiles and health conditions. CROs play a crucial role in personalized medicine by carrying out specialized trials and analyses to tailor treatments to individual genetic and biological profiles. For instance, the Personalized Medicine Coalition, a US-based non-profit organization, reports that the FDA approved 16 novel personalized therapies for rare disease patients in 2023 alone, a steep rise from the six approved in 2022. Therefore, the increasing demand for personalized medicine is substantially driving the growth of the clinical research organization market. Pre-book the report for a swift delivery: Which Industry Giants Are Powering the Clinical Research Organization Market? Major companies operating in the CRO market include Laboratory Corporation of America Holdings, IQVIA Holdings Inc., PPD Inc., ICON plc, Syneos Health Inc., Charles River Laboratories International Inc., Parexel International Corporation, Medpace Holdings Inc., Almac Group Ltd., Premier Research Group Limited, and others. These corporations have been instrumental in driving the robust growth of the clinical research market. What Noteworthy Trends Are Shaping the Future of the Clinical Research Organization Market? Emerging trends highlight that corporations in the clinical research organization market are increasingly exploring advanced solutions such as artificial intelligence AI-driven end-to-end data platforms. These platforms enhance data integration, analysis, thereby revolutionizing overall trial efficiency. For instance, Elligo Health Research Inc., a US-based clinical research organization, unveiled DataAI Connect in January 2023, a breakthrough data and technology platform engineered to expedite data-driven clinical research. How Is the Global Clinical Research Organization Market Segmented? The clinical research organization market exhibits the following key segments: 1 By Service: Drug Discovery Services, Pre-Clinical Services, Clinical Services, Post Approval Services 2 By Production: In-house, Outsourced 3 By Indication: Oncology, Central Nervous System, Cardiovascular Diseases, Metabolic Disorders, Immunology, Respiratory, Musculoskeletal Disorders, Hematological Disorders 4 By End User: Pharmaceutical And Biotechnology Companies, Medical Device Companies, Governments And Private Firms, Academic Institutions, Other End Users How Is the Clinical Research Organization Market Performing Globally? North America was the largest region in the clinical research organization market in 2023, but the Asia-Pacific region is set to surpass in the near future as the fastest-growing region during the forecasted period. The regions assessed in the clinical research organization market report span Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. Browse more similar reports- Virtual Clinical Trials Global Market Report 2024 eClinical Solutions Global Market Report 2024 Electronic Clinical Outcome Assessment Solutions Global Market Report 2024 About The Business Research Company Learn More About The Business Research Company. With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game. Contact us at: The Business Research Company: Americas +1 3156230293 Asia +44 2071930708 Europe +44 2071930708 Email us at ... Follow us on: LinkedIn: YouTube: Global Market Model: global-market-model Oliver Guirdham The Business Research Company +44 20 7193 0708 email us here Visit us on social media: Facebook X LinkedIn Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above. MENAFN12122024003118003196ID1108988704 Legal Disclaimer: MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.All smiles, perched in his gaming chair during our interview, Izaac Wang rattles off the fun things he does in his spare time, such as crafting theater performances at his fine arts high school, sharing memes on his secret Instagram account and playing popular online video games like Valorant . He wants to avoid the notion that he’s the same as Chris, his on-screen counterpart in the film Dìdi , written and directed by Sean Wang (no relation). “I’m very cool.” the actor says. “For the characters I play, I think of it as me, but in a multiverse—like Spider-Man. Chris is just me, if I was less awesome than I am right now. He’s a more vulnerable, immature, younger version of me, going through a difficult stage in his life where he’s surrounded by a community of people that aren’t as accepting as the people I have around me right now.” In Dìdi , a mid-2000s era coming-of-age tale loosely based on the filmmaker’s upbringing, Wang’s character Chris is a complicated 13-year-old Taiwanese American boy trying to navigate the adolescent pitfalls of growing up. Chris yearns for a sense of belonging as he listlessly winds down the last days of summer before starting high school. However, despite his best efforts to try and fit in, Chris’s deep-rooted insecurities cause him to constantly blunder in his relationships with not only his crush, but also his friends and family. It’s a nuanced role to capture, but a testament to Wang, who manages to emote the adolescent innocence and crass duality that Chris oscillates between on screen. According to Wang, who is 17 years old, it wasn’t much of a challenge to depict the ennui of a soon-to-be high school freshman, considering those days weren’t far behind him. “Sean is an incredible director.” Wang says. “It didn’t feel like I had to try to come across a specific feeling in a way [that would elicit] notes. One of my favorite notes to make fun of, because he always said it, was, ‘Do a scene as if you just got betrayed by one of your closest friends.’ That’s how we got through most of the dramatic stuff.” The other director’s note that kept him anchored to the spirit of a wayward teen? “Be less cool,” Wang smiles. “I try to be more confident. My dad always taught me that if you bring confidence into something you’re not confident about, you can still be confident about it. But with Chris, I had to tone that down because he’s immature and vulnerable. I had to tell myself, ‘Dammit, I have to be less cool.’ So, I guess you can say, in fact, that I am pretty cool.” Born in Minnesota to a Chinese pharmacist father and a Laotian mother, the actor was headed to Los Angeles by age three. Though Wang’s paternal grandparents added a bit of a thespian streak to the family lineage, having spent time performing Chinese theater prior to moving to the States, it was not his family that initially decided their son should join the industry—it was fate. While running a new pharmaceutical shop in Moorpark, Wang’s father, Peter, the CEO and co-founder of Honeybee Health, randomly struck up a conversation with a frequent customer who just so happened to be a kids’ talent manager. “It was a happy little accident, and from there on out, I’ve just slowly been gaining the passion to be an actor,” Wang says. This happenstance eventually led to roles in Good Boys , Clifford the Big Red Dog and a supporting role in Raya and the Last Dragon, before he landed this first leading feature film role in Dìdi . “I remember thinking because I had so many callbacks and me and Sean bonded really well that, if he doesn’t hire me, I’m going to blow up his house,” Wang says, jokingly. “I was going to quit. But then when I actually booked the job, I was ecstatic.” Taking on the responsibilities of a leading role meant new opportunities for the teen to hone his craft. His first challenge came when he had to perform a heated argument with legendary actress Joan Chen . While Dìdi primarily centers around Chris’s clumsy hijinks, the true emotional anchor is the fraught and tender relationship between mother and son. At the film’s apex, tensions arise when Chris’s mother, Chungsing (Chen), pleads with her son to make better life choices. Chris, unable to grasp her concerns, hurls a flurry of insults at her before running away. Chen’s quiet resilience, alongside Wang’s emotional fervor, perfectly encapsulates the tug of war between parental expectations and adolescent rebellion. “It’s funny because that crazy car yelling scene was my first time meeting Joan Chen.” Wang remembers, “And I can never rehearse to the same level that I can act; it’s a bit difficult sometimes, especially for dramatic scenes like that one.” To nail down the tense emotions needed, Wang’s instinct was to dive right in, no practice required, while Chen took a more seasoned approach. “Joan really wanted to rehearse, rehearse, rehearse,” Wang says, “But then, I was like, ‘We could also just do it.’ But it all ended up working out, and we got a good scene out of it.” Reflecting on the deeper thematic reasons for the constant strife between mother and son, Wang adds: “Chris has all this built-up teenage angst and rage inside of him that he just hasn’t been able to get rid of, and the only person there to rant to is his mom. It’s not that Chris despises his mom, he just doesn’t understand her. And she doesn’t understand him. But the whole thing with that scene is that you finally see the moment Chris and his mom realize that the only way to understand each other is by talking it out, not yelling at each other. The monologue that Joan has later is incredible.” Familial struggle is a resonant topic for Wang in his own life, as is the first-generation Asian American experience. There’s a delicately-balance to that portrayal, including themes packed with complexities that require a skilled hand. Wang knew he had to bring Chris’s frustrations to life in a distinctly real way and he looked to his own family for inspiration. “My mom immigrated here when she was young, and the same goes for my dad,” he says. “They had to learn how to be American [while growing up in Minnesota] in the 1990s. My mom and I used to butt heads over the most random, pointless things, mostly because we have the same personality. We’re both super stubborn and don’t give up. But the whole process of filming this movie bonded us together,” Wang admits. “And it wasn’t something that was an a-ha moment. It was over time. Whenever my mom and I would butt heads, my dad was also like our therapist—until he got tired of us—and then got us an actual therapist, that helped a lot. But being together for one month while she was my manager on set and working with her every day, I grew closer to her, mostly I think because of Chungsing and Chris’s story.” Luckily, all that work and butting of heads paid off. Wang received a Gotham Award nomination for his role, which both surprised him and affirmed his choice to move forward with his acting career. “I think of myself as chill,” he says. “I don’t get too high or too low. My brain lets me take things in without freaking out too much. But when I found out I was nominated for Breakthrough Performer, the news hit me like a truck. This acting journey has been a crazy ride and tough at times. Doubt is a monster I’ve fought with all along the way. But being recognized like this, knowing people appreciate my work, makes me feel like I’m on the right path. This is the most inspiring, encouraging— and every other synonym I can’t think of right now—news for me, and it’s fuel for my fire to keep growing. I’m still learning, and being in this profession is a privilege, so I want to do as many jobs as I can. But a well-written script that is meaningful to me and to others is always a winning combo.” Now that’s pretty cool.

NoneBXP Inc. stock underperforms Thursday when compared to competitorsBangladesh 'optimistic' of ending stalemate in relations with India during Misri visit